顺铂联合归芪益元膏调节EGFR/MAPK通路对Lewis肺癌荷瘤小鼠的影响  

Effect of cisplatin combined with Guiqi Yiyuan Ointment on Lewis lung cancer-bearing mice by regulating EGFR/MAPK pathway

在线阅读下载全文

作  者:张鹏飞 王金华 梁建庆 张惠娟 李金田 ZHANG Peng-fei;WANG Jin-hua;LIANG Jian-qing;ZHANG Hui-juan;LI Jin-tian(School of Basic Medicine,Gansu University of Traditional Chinese Medicine,Lanzhou 730000,China;School of Clinical Chinese Medicine,Gansu University of Traditional Chinese Medicine,Lanzhou 730000,China;Dunhuang Key Laboratory of Medicine and Translational Education,Lanzhou 730000,China)

机构地区:[1]甘肃中医药大学基础医学院,甘肃兰州730000 [2]甘肃中医药大学中医临床学院,甘肃兰州730000 [3]敦煌医学与转化教育部重点实验室,甘肃兰州730000

出  处:《中国中药杂志》2025年第2期472-479,共8页China Journal of Chinese Materia Medica

基  金:国家自然科学基金项目(82160872);甘肃省教育厅“双一流”科研重点项目(GSSYLXM-05);甘肃省中医药研究中心开放课题(zyzx-2020-zx17);2022年度中医学一级学科“岐黄英才”导师专项基金博导项目(ZYXKBD-202202);2022年度中医学一级学科“岐黄英才”导师专项基金硕导项目(ZYXKSD-202211);敦煌医学与转化教育部重点实验室开放课题(DHYX22-06)。

摘  要:基于表皮生长因子受体(EGFR)/丝裂原活化蛋白激酶(MAPK)通路介导的细胞增殖探讨顺铂联合归芪益元膏对Lewis肺癌荷瘤小鼠的影响。60只雄性C57BL/6小鼠随机选取10只作为空白组,剩余50只为造模组,造模成功后随机分为模型组、顺铂组以及顺铂联合归芪益元膏低、中、高剂量组,每组10只,给药14 d。观察小鼠一般情况,称重、计算脏器指数及抑瘤率;苏木素-伊红(HE)染色观察肿瘤组织病理学形态变化;免疫组化检测瘤组织中Ki-67抗原(Ki-67)和增殖细胞核抗原(PCNA)的阳性率;蛋白免疫印迹法和实时荧光定量聚合酶链式反应(qPCR)检测瘤组织中通路相关蛋白及mRNA表达;流式细胞术检测瘤组织中肿瘤细胞的周期。结果显示,与空白组比较,模型组小鼠一般情况有所恶化;给药14 d后,模型组小鼠体质量、胸腺和脾脏指数均降低。与模型组比较,顺铂组小鼠一般情况恶化,各联用组小鼠有所改善;顺铂组小鼠体质量、胸腺和脾脏指数均降低,各联用组小鼠体质量、胸腺和脾脏指数均升高;各给药组瘤重降低,抑瘤率升高;肿瘤细胞均有不同程度的坏死,且肿瘤细胞紧密度、细胞核和染色质增多情况、核分裂均降低;各给药组Ki-67和PCNA的阳性率,p-EGFR/EGFR、肉瘤病毒癌基因(Ras)、磷酸化Raf-1蛋白激酶(p-Raf-1)/Raf-1、磷酸化丝裂原活化蛋白激酶激酶(p-MEK)/MEK、磷酸化细胞外信号调节激酶(p-ERK)/ERK水平,EGFR、Ras、Raf-1、MEK、ERK mRNA的表达均降低;各给药组肿瘤细胞G0/G1期比例升高,S期比例降低,G2/M期无显著差异。与顺铂组比较,各联用组瘤重降低,抑瘤率升高;肿瘤细胞的坏死及核分裂降低等情况更为显著;Ki-67和PCNA的阳性率,p-EGFR/EGFR、Ras、p-Raf-1/Raf-1、p-MEK/MEK、p-ERK/ERK水平,EGFR、Ras、Raf-1、MEK、ERK mRNA的表达均降低。与顺铂组比较,联用中、高剂量组肿瘤细胞G0/G1期比例升高,S期比例降低;各联用组肿瘤细胞Based on the epidermal growth factor receptor(EGFR)/mitogen-activated protein kinase(MAPK)signaling pathwaymediated cell proliferation,this study explores the effect of cisplatin combined with Guiqi Yiyuan Ointment on Lewis lung cancerbearing mice.A total of 60 male C57BL/6 mice were randomly divided into a blank group with 10 mice and a modeling group with 50 mice.After modeling,they were randomly divided into the model group,cisplatin group,and low-,medium-,and high-dose groups of cisplatin combined with Guiqi Yiyuan Ointment,with 10 mice in each group.After 14 days of medication,the general condition of the mice was observed;body weight was measured,and organ index and tumor inhibition rate were calculated.Hematoxylin-eosin(HE)staining was used to observe the pathological morphology changes in tumor tissue.Immunohistochemistry was used to detect the positive rate of Ki-67 antigen(Ki-67)and proliferating cell nuclear antigen(PCNA)in tumor tissue.Western blot and real time-quantitative polymerase chain reaction(qPCR)were used to detect the expression of related proteins and mRNA in tumor tissue.Flow cytometry was used to detect the cell cycle of tumor cells in tumor tissue.The results showed that compared with that in the blank group,the general condition of mice in the model group deteriorated;the body weight,as well as thymus and spleen index of mice in the model group decreased after 14 days of medication.Compared with that in the model group,the general condition of mice in the cisplatin group deteriorated,while the condition of mice in the combined groups improved;the body weight,as well as thymus and spleen index of mice in the cisplatin group decreased,while the three indicators in the combined groups increased;the tumor weight of each medication group decreased,and the tumor inhibition rate increased;there were varying degrees of necrosis in tumor cells of each medication group,and the tightness of tumor cells,the increase in the number of cell nuclei and chromatin,and mitosis all decreased.The positive

关 键 词:顺铂 归芪益元膏 EGFR/MAPK通路 增殖 周期阻滞 

分 类 号:R285.5[医药卫生—中药学]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象